CN Patent

CN113631192B — 抑制乙型肝炎病毒蛋白产生的医药组合物、用于处置乙型肝炎的医药组合物及筛选方法

Assigned to Fujifilm Corp · Expires 2023-07-21 · 3y expired

What this patent protects

本发明的课题在于提供一种作为新型抗乙型肝炎病毒剂有用的医药组合物及筛选方法。根据本发明，可提供一种抑制乙型肝炎病毒蛋白产生的医药组合物，所述医药组合物的特征在于，抑制属于YTHDC家族的蛋白的表达或功能。

USPTO Abstract

本发明的课题在于提供一种作为新型抗乙型肝炎病毒剂有用的医药组合物及筛选方法。根据本发明，可提供一种抑制乙型肝炎病毒蛋白产生的医药组合物，所述医药组合物的特征在于，抑制属于YTHDC家族的蛋白的表达或功能。

Drugs covered by this patent

dordaviprone-hydrochloride (DORDAVIPRONE HYDROCHLORIDE)

Patent Metadata

Patent number: CN113631192B
Jurisdiction: CN
Classification: —
Expires: 2023-07-21
Drug substance claim: No
Drug product claim: No
Assignee: Fujifilm Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.